Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Item
http://www.wikidata.org/entity/Q33677550
Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.Nephrotoxicity comparison of two commercially available generic vancomycin products.Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays.Factors impacting unbound vancomycin concentrations in different patient populations.Elution and Mechanical Strength of Vancomycin-Loaded Bone Cement: In Vitro Study of the Influence of Brand CombinationComparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.Overview of therapeutic drug monitoring.Three structurally-related impurities in norvancomycin drug substance.Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities.Clinical utility of antibiotic-loaded hydroxyapatite block for treatment of intractable periprosthetic joint infection and septic arthritis of the hip.Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.Variability in telavancin cross-reactivity among vancomycin immunoassays.Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: time for a change.Analysis of vancomycin and related impurities by micellar electrokinetic capillary chromatography. Method development and validation.Bone grafts as vancomycin carriers in local therapy of resistant infections.Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
P2860

Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Item
http://www.wikidata.org/entity/Q33677550
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Implications of vancomycin deg ...... with end-stage renal disease.
@ast
Implications of vancomycin deg ...... with end-stage renal disease.
@en
type
label
Implications of vancomycin deg ...... with end-stage renal disease.
@ast
Implications of vancomycin deg ...... with end-stage renal disease.
@en
prefLabel
Implications of vancomycin deg ...... with end-stage renal disease.
@ast
Implications of vancomycin deg ...... with end-stage renal disease.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Implications of vancomycin deg ...... with end-stage renal disease.
@en
P2093
P2860
P304
P31
P356
10.1592/PHCO.19.9.702.31548
P407
P433
P478
P577
P698